REG - Aptamer Group PLC - Licensing agreed for Optimer as vaccine adjuvant

AptamerAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250430:nRSd7095Ga&default-theme=true

RNS Number : 7095G  Aptamer Group PLC  30 April 2025

 

30 April 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Licensing agreed for Optimer as novel vaccine adjuvant

 

Successful project delivery of Optimer binders with proven function as vaccine
adjuvants

Aptamer to receive 10% royalties on downstream sales of any Optimer-containing
vaccines

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, has
entered into a global licensing agreement with the University of Glasgow for
the commercial use of a developed panel of Optimer binders as vaccine
adjuvants in the swine health sector.

 

Under the terms of the agreement, the University of Glasgow receives exclusive
rights to a panel of Optimers for use as adjuvants in vaccine development. The
University will lead product development, with commercialisation anticipated
within the next 12 months. Aptamer will receive a 10% royalty on all future
revenues from any vaccines incorporating the licensed Optimers, creating a
scalable, global, non-dilutive revenue stream.

 

This partnership provides Aptamer access to the $1.75 billion global swine
vaccine market (2024)(1), an industry experiencing sustained demand for
improved animal health solutions. The licensed Optimers, originally developed
under a fee-for-service model, have demonstrated strong immune-enhancing
capabilities in preclinical studies led by the University of Glasgow,
suggesting significant potential for their use in improving immune response
and health outcomes in pigs, an area of major interest within the global
veterinary and agricultural markets.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer, said: "This licensing
deal represents an important milestone in the commercialisation of our Optimer
technology. It demonstrates our ability to deliver high-value solutions across
diverse sectors and builds on our strategic focus of monetising Optimer-based
assets beyond our core focus in human health. With growing demand for advanced
animal health solutions, this partnership creates a global pathway to
recurring revenues while validating the robustness and versatility of our
Optimer platform.

 

This agreement reinforces Aptamer's broader commercial strategy of leveraging
its proprietary platform across multiple verticals, including targeted drug
delivery for human therapeutics, diagnostics, personal care, research
reagents, and now veterinary vaccines, to generate long-term shareholder
value."

 

(1.) Grand View Research. Swine Vaccines Market Size, Share & Trends
Analysis Report By Product (Inactivated, Modified/Attenuated Live), By Type
(Pseudorabies, Porcine Circovirus Type 2), By Route Of Administration, By
Region, And Segment Forecasts, 2025 - 2030. Report ID: GVR-4-68039-728-0

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next generation synthetic binders
delivering innovation to the life sciences industry. The Group
develops Optimer® binders, advanced molecules that work like antibodies by
attaching to specific targets in the body. These binders are used
in medicine, diagnostic tests, and research tools, offering benefits
like high stability, reliable performance, and lower costs compared to
traditional antibodies.

 

Aptamer operates a fee-for-service business in the $210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners,
aiming for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTDKLFLEZLEBBX